Evidence map›Paper›PMID 28870240›Full record

ArticleBiological research2017

Neuron-derived CCL2 contributes to microglia activation and neurological decline in hepatic encephalopathy.

Li Zhang, Jinyun Tan, Xiaoping Jiang, Weiwei Qian, Ting Yang, Xijun Sun, Zhaohui Chen, Qiwen Zhu

Open access · goldAbstract read
In one paragraph

Article in Biological research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 55 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Golexanolone, a GABACNS neuroscience & therapeutics · 2022
    Article
  14. Article
  15. Article
  16. Article
  17. The neurogliovascular unit in hepatic encephalopathy.JHEP reports : innovation in hepatology · 2021
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Li ZhangDepartment of Radiology, The Second People's Hospital of Lanzhou, No. 388 Jingyuan Road, Chengguan District, Lanzhou, 730046, China.
Jinyun TanDepartment of Radiology, The Second People's Hospital of Lanzhou, No. 388 Jingyuan Road, Chengguan District, Lanzhou, 730046, China.
Xiaoping JiangDepartment of Radiology, The Second People's Hospital of Lanzhou, No. 388 Jingyuan Road, Chengguan District, Lanzhou, 730046, China. jiang5xp@sina.com.
Weiwei QianDepartment of Radiology, The Second People's Hospital of Lanzhou, No. 388 Jingyuan Road, Chengguan District, Lanzhou, 730046, China.
Ting YangDepartment of Radiology, The Second People's Hospital of Lanzhou, No. 388 Jingyuan Road, Chengguan District, Lanzhou, 730046, China.
Xijun SunDepartment of Radiology, The Second People's Hospital of Lanzhou, No. 388 Jingyuan Road, Chengguan District, Lanzhou, 730046, China.
Zhaohui ChenDepartment of Radiology, The Second People's Hospital of Lanzhou, No. 388 Jingyuan Road, Chengguan District, Lanzhou, 730046, China.
Qiwen ZhuDepartment of Radiology, The Second People's Hospital of Lanzhou, No. 388 Jingyuan Road, Chengguan District, Lanzhou, 730046, China.
Lanzhou University · CNXian Yang Central Hospital · CNLanzhou University Second Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCCL2 was up-regulated in neurons and involved in microglia activation and neurological decline in mice suffering from hepatic encephalopathy (HE). However, no data exist concerning the effect of neuron-derived CCL2 on microglia activation in vitro.

methodsThe rats were pretreated with CCL2 receptor inhibitors (INCB or C021, 1 mg/kg/day i.p.) for 3 days prior to thioacetamide (TAA) administration (300 mg/kg/day i.p.) for inducing HE model. At 8 h following the last injection (and every 4 h after), the grade of encephalopathy was assessed. Blood and whole brains were collected at coma for measuring CCL2 and Iba1 expression. In vitro, primary neurons were stimulated with TNF-α, and then the medium were collected for addition to microglia cultures with or without INCB or C021 pretreatment. The effect of the medium on microglia proliferation and activation was evaluated after 24 h.

resultsCCL2 expression and microglia activation were elevated in the cerebral cortex of rats received TAA alone. CCL2 receptors inhibition improved neurological score and reduced cortical microglia activation. In vitro, TNF-α treatment induced CCL2 release by neurons. Medium from TNF-α stimulated neurons caused microglia proliferation and M1 markers expression, including iNOS, COX2, IL-6 and IL-1β, which could be suppressed by INCB or C021 pretreatment. The medium could also facilitate p65 nuclear translocation and IκBα phosphorylation, and NF-κB inhibition reduced the increased IL-6 and IL-1β expression induced by the medium.

conclusionNeuron-derived CCL2 contributed to microglia activation and neurological decline in HE. Blocking CCL2 or inhibiting microglia excessive activation may be potential strategies for HE.

Indexed as

AnimalsChemokine CCL2Culture MediaDisease Models, AnimalGene ExpressionHepatic EncephalopathyInterleukin-6MicrogliaNervous System DiseasesNeuronsRatsReceptors, ChemokineThioacetamideCcl2 protein, mouseCcl2 protein, ratChemokine CCL2Culture MediaInterleukin-6Receptors, ChemokineThioacetamideChemokine CC motif ligand 2Hepatic encephalopathyMicrogliaNeuron

Identifiers

PMID28870240
PMCPMC5584513
OpenAlexW2752477272

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.